Mariela Mejia Cordova
Forskningsingenjör vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Angelica Loskog
- E-post:
- mariela.mejia_cordova@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Urval av publikationer
- Assessing the Effectiveness of Interleukin-2 Therapy in Experimental Type 1 Diabetes (2024)
- CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling (2024)
- Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells (2021)
- Kinetics of immune cell responses in the multiple low dose streptozotocin mouse model of type 1 diabetes (2019)
- Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas (2018)
- Role of regulatory B cells in clinical and experimental type 1 diabetes (2017)
- Kinetics of the innate immune cell responses in experimental Type 1 Diabetes (2017)
Senaste publikationer
- Assessing the Effectiveness of Interleukin-2 Therapy in Experimental Type 1 Diabetes (2024)
- CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling (2024)
- Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells (2021)
- The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors (2019)
- Kinetics of immune cell responses in the multiple low dose streptozotocin mouse model of type 1 diabetes (2019)
Alla publikationer
Artiklar
- Assessing the Effectiveness of Interleukin-2 Therapy in Experimental Type 1 Diabetes (2024)
- CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling (2024)
- Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells (2021)
- The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors (2019)
- Kinetics of immune cell responses in the multiple low dose streptozotocin mouse model of type 1 diabetes (2019)
- Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas (2018)
- Role of regulatory B cells in clinical and experimental type 1 diabetes (2017)
- Kinetics of the innate immune cell responses in experimental Type 1 Diabetes (2017)
